PIVOT 006 Lowers Bladder Tumor Recurrence

Company CG Oncology Event Type Phase 3 topline (PIVOT-006) Modality Intravesical oncolytic immunotherapy Asset Cretostimogene grenadenorepvec Target Urothelial tumor cells (oncolysis and immune activation) Disease Area Intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer Summary CG Oncology reported a Phase 3 recurrence-free-survival hazard ratio of 0.32…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *